TABLE 3.
Oligonucleotides used in this study
| Designation | Sequence (5′ to 3′) | Target gene | Position | Reference |
|---|---|---|---|---|
| Primers | ||||
| HO1 | GCT ACG CAT ACC CGC GTT GC | cppB | 3141–3160 | 7 |
| HO3 | CGA AGA CCT TCG AGC AGA CA | cppB | 3512–3531 (antia) | 7 |
| cppBN1 | GCT GTT TCA AGT CGT CCA GC | cppB | 3250–3269 | This study |
| cppBN2 | CGA AGC CGC CAG CAT AGA GC | cppB | 3484–3503 (anti) | This study |
| cppBN3 | GCT GTT TCA AGT CGT | cppB | 3250–3264 | This study |
| cppBN4 | Biotin-CGA AGC CGC CAG CAT | cppB | 3489–3503 (anti) | This study |
| SL67 | TAT CGG AAC GTA CCG GGT AGC | 16S rRNA | 124–144 | 12 |
| SL59 | GTA TTA CCG CGG CTG CTG GCA | 16S rRNA | 517–537 (anti) | 12 |
| Probes | ||||
| cppBPB1 | GCT ATG ACT ATC AAC CCT GCC GCC G | cppB | 3306–3330 | This study |
| SL80E | GGC CGC CGA TAT TGG CAA CA | 16S rRNA | 459–478 (anti) | 12 |
a
anti, antisense sequence.